Cardiovascular, Metabolic

The contract between this chapter and the reader.

1. 1. Recognise cardiovascular disease as the leading cause of death with a functioning graft.
2. 2. Reduce cardiovascular risk after transplant.
3. 3. Explain and manage post-transplant diabetes.
4. 4. Manage post-transplant dyslipidemia.
5. 5. Manage post-transplant hypertension.
6. 6. Recognise and manage post-transplant mineral-bone disease.
7. 7. Link each complication to its immunosuppressive driver.
8. 8. Recognise other metabolic complications.
9. 9. Modify immunosuppression where it drives a complication.

A sixty-second reading. Each bullet stands alone.

• With a functioning graft, cardiovascular disease is the leading cause of death.
• The chronic complications are driven by immunosuppression plus traditional risk factors and prior CKD.
• Cardiovascular risk is reduced with statins, blood-pressure and glycemic control, and lifestyle.
• Post-transplant diabetes arises from steroids and calcineurin inhibitors (tacrolimus more than ciclosporin).
• Post-transplant diabetes is screened for and managed by lifestyle, glucose-lowering therapy, and immunosuppression modification.
• Dyslipidemia is common, worsened by mTOR inhibitors, and treated with statins, watching the calcineurin-inhibitor interaction.
• Hypertension is common, driven by calcineurin inhibitors and steroids; calcium-channel blockers help.
• Persistent (tertiary) hyperparathyroidism may continue after transplant and sometimes needs treatment.
• Steroids cause rapid early bone loss and, occasionally, avascular necrosis.
• Early hypophosphatemia is common after transplant.
• Each complication is linked to a drug — tacrolimus and steroids to diabetes, mTOR inhibitors to lipids, calcineurin inhibitors to hypertension.
• Where a drug drives a complication, immunosuppression is modified, balanced against rejection risk.
• The graft is managed with aggressive cardiovascular risk reduction and metabolic and bone monitoring.

The medical core. An expert should agree the cardiometabolic and bone complications are fully covered here.

Why it matters at the bedside

Asuccessful transplant trades the risks of dialysis for a new set of long-term hazards — and the commonest way to lose a recipient is not to lose the graft, but to lose the patient to a heart attack. The chronic medical complications, most of them stoked by the very drugs that protect the graft, are what determine how long and how well a recipient lives, so managing them is not an afterthought but the long game.

The big picture: dying with a functioning graft

• ‘Death with a functioning graft’ is a leading mode of graft loss, and its commonest cause is cardiovascular disease. The chronic complications — cardiovascular disease, diabetes, dyslipidemia, hypertension, and bone disease — arise from three sources stacked together: the patient's pre-existing CKD and dialysis-era risk, traditional risk factors, and the immunosuppression itself. Recognising the drug contribution is what makes them modifiable.

Cardiovascular disease

• Cardiovascular disease is the leading cause of death with a functioning graft, the end-point toward which diabetes, hypertension, and dyslipidemia all push. Management is aggressive risk reduction — statins, blood-pressure control, glycemic control, lifestyle change, and antiplatelet therapy where indicated — applied as assiduously as in any high-risk cardiovascular population, because this is what recipients most often die of.

Post-transplant diabetes

• New-onset diabetes after transplant (post-transplant diabetes mellitus) is common, driven by corticosteroids and calcineurin inhibitors — tacrolimus more than ciclosporin — on a background of traditional risk. It is screened for with glucose and HbA1c and managed by lifestyle, glucose-lowering therapy (oral agents or insulin), and, where feasible, immunosuppression modification (steroid minimisation, adjusting the calcineurin inhibitor). It compounds cardiovascular risk.

Dyslipidemia

• Dyslipidemia is common after transplant and notably worsened by mTOR inhibitors (which cause marked hyperlipidemia), with contributions from calcineurin inhibitors and steroids. It is treated with statins — with attention to the interaction between statins and calcineurin inhibitors, which raises the risk of statin myopathy, so doses are chosen carefully.

Hypertension

• Hypertension is highly prevalent, driven by calcineurin-inhibitor vasoconstriction, corticosteroids, the native kidneys, graft dysfunction, and transplant renal artery stenosis (its own chapter). It is controlled with the usual agents; calcium-channel blockers are particularly useful because they counter calcineurin-inhibitor vasoconstriction, while ACE inhibitors and ARBs are renoprotective but used with care for hyperkalemia and the creatinine rise that can unmask stenosis.

Mineral-bone disease

• Bone and mineral disease after transplant has several strands: persistent (tertiary) hyperparathyroidism may continue, causing hypercalcemia and needing cinacalcet or parathyroidectomy; corticosteroids cause rapid, early bone loss and occasionally avascular necrosis; and early post-transplant hypophosphatemia is common. Management is monitoring PTH, calcium, phosphate, and vitamin D, with bone protection (vitamin D, selective bisphosphonates) and steroid minimisation.

Other metabolic complications

• Other complications round out the picture: weight gain and obesity (steroids), gout and hyperuricemia (calcineurin inhibitors — and the dangerous azathioprine-allopurinol interaction met earlier), and post-transplant erythrocytosis. Each is recognised and managed in its own right.

Linking complications to drugs

• The unifying insight is that most of these complications carry a drug's fingerprint: tacrolimus and steroids to diabetes, mTOR inhibitors to hyperlipidemia, calcineurin inhibitors to hypertension and gout, steroids to bone loss and weight. Naming the driver turns a complication into something potentially modifiable at its source, not just treated symptomatically.

Modifying immunosuppression

• Where a drug is driving a complication, immunosuppression can be modified — steroid minimisation for diabetes and bone loss, reducing or switching the calcineurin inhibitor, converting off an mTOR inhibitor for hyperlipidemia — always weighed against the rejection risk of changing the regimen. It is the same balance that runs through the immunosuppression chapters, applied here to metabolic harm.

General management

• Overall, the recipient is managed as a high-cardiovascular-risk patient: aggressive risk-factor control, screening for and treating diabetes, dyslipidemia, and hypertension, monitoring and protecting bone, modifying immunosuppression where it drives harm, and supporting lifestyle — the unglamorous long game that determines survival once the graft is working.

Five fully-built tables.

Table A — Complications and their drug drivers

Table B — Cardiovascular risk reduction

Table C — Post-transplant diabetes

Table D — Mineral-bone disease

Table E — Immunosuppression modification

Visualise & Map

Causal chains, each ending in a named action.

Chain 1 — Steroids and tacrolimus to diabetes

Steroids + tacrolimus → insulin resistance and impaired insulin secretion → post-transplant diabetes → ACTION: screen, treat, and consider immunosuppression modification.

Chain 2 — mTOR and lipids

mTOR inhibitor → marked hyperlipidemia → added cardiovascular risk → ACTION: treat with a statin and consider conversion off the mTOR inhibitor.

Chain 3 — CNI and pressure

Calcineurin inhibitor → afferent vasoconstriction and sodium retention → hypertension → ACTION: control blood pressure, favouring a calcium-channel blocker.

Chain 4 — Steroids and bone

Corticosteroids → rapid early bone loss (and occasionally avascular necrosis) → fracture risk → ACTION: protect bone and minimise steroids.

Chain 5 — The common end-point

Pre-existing CKD risk + drug-driven diabetes/hypertension/dyslipidemia → accelerated atherosclerosis → cardiovascular death (the leading cause) → ACTION: reduce cardiovascular risk aggressively.

Numbered rules. These numbers are the cross-reference handle for the cases and flowcharts.

Clinical Reasoning

Five cases. Each stops you at a decision before it answers it.

Every mechanism from Level 3 earns a bedside consequence and an action.

Exhaustive. Every rule in the chapter is here.

Safety & Evidence

Panel A — Red flags

Panel B — NEVER DO

Anti-patterns clinicians fall into. Each becomes a Level 22 distractor.

The grade reflects strength of evidence, not importance.

Patient Decisions

Outcomes as natural frequencies. Figures are representative; the direction of effect is given where precise numbers are uncertain.

Apply & Test

Copy-paste chart notes that map to the real decisions in this chapter.

Template 1 — Cardiometabolic risk review note

• Cardiovascular risk: history, risk factors; statin / antiplatelet status ___.
• Diabetes: glucose / HbA1c; PTDM present? therapy ___.
• Lipids: profile; statin (CNI interaction considered) ___.
• Blood pressure: control; agent (CCB?) ___.
• Immunosuppression modification considered for any driver: ___.

Template 2 — Bone / mineral management note

• PTH, calcium, phosphate, vitamin D: ___.
• Tertiary hyperparathyroidism? cinacalcet / parathyroidectomy ___.
• Bone density / fracture risk; bone protection (vitamin D, bisphosphonate) ___.
• Steroid minimisation considered: ___.
• Early hypophosphatemia / other metabolic issues: ___.

Pre-rounds compression. Rules only.

Active recall. At least one card per objective.

Micro-teaching for rounds. Two scenarios, five steps each.

Nine items, each anchored in this chapter. At least one per objective.